Gastrointestinal OTC Drugs Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Gastrointestinal OTC Drugs Market Trends and Insights

Rising Burden of Heartburn, Constipation, and Acute Gastrointestinal Symptoms

The gastrointestinal OTC drugs market benefited from the recurring prevalence of heartburn, constipation, and acute digestive symptoms, which consumers commonly managed without prescriptions. Dietary habits, sedentary lifestyles, aging populations, and obesity sustained demand for acid-relief and constipation products, with obesity linked to both GERD and constipation. Heartburn and indigestion supported demand for low-cost antacids and acid-suppression products, while low fiber intake and limited activity drove laxative demand. In 2026, a systematic review reported gastrointestinal adverse effects in 50%–60% of patients initiating GLP-1 receptor agonists, supporting demand for antacids, anti-diarrheals, fiber products, and anti-emetics.^{[1]“Exploring the Side Effects of GLP-1 Receptor Agonists,” PubMed Central, pmc.ncbi.nlm.nih.gov.}

OTC Switches and Broader Access to Acid-Control Therapies

The gastrointestinal OTC drugs market gained momentum from prescription-to-OTC switches for acid-control therapies. Japan approved the Rx-to-OTC switch of Pariet S, a rabeprazole product, in 2025, and Eisai subsequently launched it as Japan’s first proton pump inhibitor to transition from prescription status to OTC availability. In the United States, the FDA’s Additional Condition for Nonprescription Use rule became effective on May 27, 2025, enabling additional conditions such as technology-assisted processes or pharmacist consultation when labeling alone was insufficient.^{[2]“Additional Condition for Nonprescription Use Final Rule,” Federal Register, govinfo.gov.} These developments expanded consumer access but also increased the need for pharmacist guidance, while creating greater price competition from retailers and generic suppliers.

E-Commerce and Omnichannel Availability of Digestive-Health Products

Digital channels strengthened product discovery and repeat purchases in the gastrointestinal OTC drugs market through online pharmacies, quick-commerce platforms, and modern retail formats. Bayer introduced Dulcolax-branded lactulose in China through a collaboration with JD Health in July 2025, using consumer data to develop cylindrical packaging for e-commerce channels and younger urban consumers. Bayer also launched Alka-Seltzer in India in June 2026 through e-pharmacies, quick-commerce, and modern retail channels. The company planned distribution through 100,000 retail outlets and outreach to 100 million households over four years, while online pharmacy growth increased the need for compliance with regional consumer data privacy requirements.

GLP-1-Associated Gastrointestinal Symptom Management

GLP-1 receptor agonists created a distinct consumer segment requiring support for nausea, diarrhea, and constipation associated with delayed gastric emptying and reduced intestinal motility. These symptoms could affect treatment persistence and daily comfort, particularly in markets with broader GLP-1 access. Procter & Gamble promoted Metamucil fiber products for consumers on a GLP-1 treatment journey, focusing on regularity support rather than prescription-linked claims. The current product portfolio primarily addressed these symptoms through existing stock-keeping units, while potential combination anti-emetic and anti-diarrheal products would require appropriate evidence and regulatory clearance.

Safety Concerns and Misuse of Long-Term Acid Suppression

Safety concerns limited the repeat use of acid-suppression products without appropriate guidance. Reviews published in 2025 and 2026 discussed potential associations between long-term proton pump inhibitor use and several health outcomes, although causal relationships remained difficult to establish in some cases.^{[3]“Emerging Long-Term Risks of the Use of Proton Pump Inhibitors and Potassium-Competitive Acid Blockers,” Annual Review of Medicine, annualreviews.org.} These concerns made pharmacists and healthcare providers more cautious about repeated self-treatment. The gastrointestinal OTC drugs market needed to balance accessibility with clear use instructions, referral guidance, and appropriate labeling. Community pharmacies also helped consumers distinguish occasional heartburn from symptoms requiring medical assessment, particularly as more prescription-grade therapies became available over the counter.

Retailer Private-Label and Price-Led Substitution

Private-label products created sustained pricing pressure in mature OTC categories, particularly for antacids, laxatives, and anti-diarrheals containing long-off-patent active ingredients. Retailer brands offered comparable formulations at lower prices than established brands, encouraging price-led substitution. Perrigo reported store-brand share gains in laxative categories in its third-quarter 2025 results, while store-brand PPI consumption declined during the period. Prescription-to-OTC switches increased category volumes but also intensified price competition, which could limit margin benefits for originator brands. Branded companies used gummies, probiotic combinations, and fast-dissolve formats to differentiate their offerings. 

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Drug Class: Antacids Lead, While PPIs Increase Access to Longer-Lasting Relief

Antacids held 28.67% of the gastrointestinal OTC drugs market share by drug class in 2025. Their leading position reflected broad availability, affordable pricing, and rapid relief for occasional symptoms within 1–5 minutes. Laxatives, antidiarrheals, antiemetics, and H2 receptor antagonists, including famotidine- and cimetidine-based products, also maintained demand across self-managed gastrointestinal conditions.

Proton pump inhibitors (PPIs) are forecast to record the highest growth at a CAGR of 5.67% from 2026 to 2031. Japan’s 2025 switch approvals and the U.S. ACNU pathway supported access to PPIs for recurring reflux management. While PPIs provide sustained acid suppression, safety concerns reinforce the need for pharmacist guidance and support demand for digestive enzymes, simethicone, and specialty products.

By Indication: Heartburn and Indigestion Lead, While GERD Has the Highest Growth Rate

Heartburn and indigestion held 32.44% of the indication-based market share in 2025. The gastrointestinal OTC drugs market addressed short-term post-meal discomfort and recurring symptom management, with antacids commonly used for immediate relief. Constipation, diarrhea, nausea, vomiting, gas, flatulence, and bloating also supported demand for self-medication products, including simethicone and probiotic-oriented offerings.

GERD is forecast to grow at a CAGR of 6.23% from 2026 to 2031. This segment reflects demand for sustained acid control, leading consumers to prefer PPIs and H2 receptor antagonists over traditional antacids. Regulatory switches improved pharmacy access; however, persistent symptoms require pharmacist guidance and may need medical evaluation.

By Formulation: Tablets Retain Scale, While Gummies Change Consumer Preferences

Tablets held 38.45% of the gastrointestinal OTC drugs market share by formulation in 2025, supported by familiar dosing, shelf stability, and low manufacturing costs. Capsules and softgels remained important for delayed-release PPIs and digestive enzymes, while liquids and suspensions served pediatric diarrhea, vomiting, and rapid antacid relief needs. Effervescent granules and tablets also remained relevant in markets familiar with fast-dissolving formats.

Chewable tablets and gummies are forecast to grow at a CAGR of 6.67% from 2026 to 2031. Haleon cited Tums Gummy Bites as a digestive-health growth contributor in its 2025 results, while Procter & Gamble offers Pepto-Bismol in gummy formats. Fast-dissolve strips and powders further provide travel convenience and improve product acceptability among children.

By Route of Administration: Oral Products Dominate, While Rectal Products Address Specific Needs

Oral products held 89.34% of the route-of-administration market share in 2025. The gastrointestinal OTC drugs market used oral delivery for antacids, PPIs, H2 receptor antagonists, laxatives, and antidiarrheals. Chewable, effervescent, and fast-dissolving formats improved accessibility for older adults and pediatric users with difficulty swallowing standard tablets, while topical products maintained a stable role in hemorrhoid management.

Rectal products are forecast to grow at a CAGR of 5.77% through 2031. Glycerin suppositories, bisacodyl formulations, and microenemas support consumers with severe constipation who cannot tolerate oral laxatives. Perrigo’s GoodSense bisacodyl rectal product remained actively listed in U.S. OTC records, and the FDA OTC laxative monograph provided an established framework for eligible products.

By Distribution Channel: Retail Pharmacies Lead, While Online Pharmacies Expand Convenience

Retail pharmacies held 49.45% of the distribution channel share in 2025. Pharmacists helped consumers select products based on symptoms and intended duration of use, while in-store promotions supported acute digestive health categories. Supermarkets and hypermarkets remained relevant for antacid and laxative purchases, and hospital pharmacies served discharge-related and short-term symptom management needs.

Online pharmacies are forecast to grow at a CAGR of 4.87% through 2031. Bayer’s China collaboration and India launch placed digital access at the center of product availability, while recurring-delivery models supported repeat purchases. Online channels also enabled private purchases, although retail pharmacy guidance remained important for consumers with persistent or unusual symptoms.

Geography Analysis

North America held 40.44% of the gastrointestinal OTC drugs market share in 2025, supported by high OTC healthcare spending and mature retail pharmacy infrastructure. The FDA’s ACNU rule, effective in May 2025, supported nonprescription access for products requiring additional conditions for safe use. This framework could support future switches for acid-control and anti-diarrheal products. Canada aligned closely with U.S. regulatory standards, while Mexico followed the COFEPRIS framework.

Europe remained the second-largest regional market, although country-specific requirements slowed coordinated product launches. Community pharmacies played a key advisory role in France, Italy, and Spain by supporting product selection and referrals for persistent symptoms. Private-label competition remained significant in the United Kingdom and Germany, where store brands occupied substantial supermarket and pharmacy shelf space. The region combined strong self-care demand with a focus on pricing and professional guidance.

Asia-Pacific is forecast to grow at a CAGR of 6.98% from 2026 to 2031. China held 36.05% of the Asia-Pacific OTC drugs market in 2025, supported by urban e-commerce access, while India is expected to register the highest sub-regional CAGR. Bayer expanded Alka-Seltzer in India across 100,000 retail outlets, targeting 100 million households over four years. South America, the Middle East, and Africa offer long-term potential through expanding pharmacy networks, self-care regulations, and digital retail access.